We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
In this difficult consumer environment, biopharmaceutical companies’ investment in free drug programs is more important than ever, particularly for uninsured, underinsured or low-income patients who need access and long-term adherence to expensive special